<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654550</url>
  </required_header>
  <id_info>
    <org_study_id>NEX-OCU-001</org_study_id>
    <nct_id>NCT00654550</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness</brief_title>
  <official_title>A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OcuNexus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OcuNexus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 randomized, prospective, double-masked, vehicle-controlled, dose-escalation study to&#xD;
      evaluate the safety, tolerability and clinical effect of Nexagon™ in subjects following&#xD;
      bilateral PRK for the correction of mild to moderate myopia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>30 days post-application</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the clinical effect of Nexagon™</measure>
    <time_frame>30 days post-application</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Corneal re-Epithelialization</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexagon™ or Nexagon™ vehicle</intervention_name>
    <description>Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female pre-presbyopic myopes.&#xD;
&#xD;
          -  Aged between 20 and 50 years inclusive.&#xD;
&#xD;
          -  Females are eligible to participate only if they are currently non-pregnant and&#xD;
             non-lactating. Females of child-bearing potential must commit to consistent and&#xD;
             correct use of an acceptable method of birth control.&#xD;
&#xD;
          -  Subjects willing and able to undergo bilateral PRK for the correction of their myopia.&#xD;
&#xD;
          -  Subjects with MRSE &lt;6.0 D, with less than 2.0 D of astigmatism.&#xD;
&#xD;
          -  No more than 1.0 D of refractive difference between eyes.&#xD;
&#xD;
          -  Stable prescription in both eyes as defined by &lt;0.25 D change over the preceding 2&#xD;
             years.&#xD;
&#xD;
          -  Subjects who are able to comply with all study procedures, including wearing a soft&#xD;
             bandage contact lens in the immediate postoperative period.&#xD;
&#xD;
          -  Subjects who are willing and able to give written informed consent to take part in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a past or present disease, which as judged by the investigator may&#xD;
             affect the safety of the subject or the outcome of the study.&#xD;
&#xD;
          -  Subjects who have previously had corneal surgery.&#xD;
&#xD;
          -  Subjects who require Mitomycin C following their PRK.&#xD;
&#xD;
          -  Subjects with any ocular disease or corneal abnormality, including but not limited to:&#xD;
&#xD;
               -  Decreased corneal sensation / neurotrophic cornea;&#xD;
&#xD;
               -  Corneal vascularization;&#xD;
&#xD;
               -  Keratoconus;&#xD;
&#xD;
               -  Keratoconjunctivitis sicca requiring chronic treatment;&#xD;
&#xD;
               -  Lagophthalmos;&#xD;
&#xD;
               -  Blepharitis;&#xD;
&#xD;
               -  History of infectious keratitis;&#xD;
&#xD;
               -  History of glaucoma or intraocular pressure of &gt;21 mmHg or use of glaucoma&#xD;
                  medications;&#xD;
&#xD;
               -  Significant dry eye disease that requires regular topical treatment;&#xD;
&#xD;
               -  Corneal thickness &lt;480 µm at the thinnest point, and&#xD;
&#xD;
               -  Posterior elevation &gt;40 mmHg.&#xD;
&#xD;
          -  Subjects with corneal haze &gt;+1 as assessed using the grading scale in the protocol.&#xD;
&#xD;
          -  Subjects who require any topical ophthalmic medication other than the pre- and&#xD;
             postoperative regimen defined in the study protocol.&#xD;
&#xD;
          -  Subjects with:&#xD;
&#xD;
               -  Diabetes;&#xD;
&#xD;
               -  Collagen disorders associated with autoimmune diseases, e.g., lupus, rheumatoid&#xD;
                  arthritis;&#xD;
&#xD;
               -  Severe atopic disease;&#xD;
&#xD;
               -  Any systemic disease or condition where the subject is immunocompromized.&#xD;
&#xD;
          -  Subjects who require any systemic medication that affects healing, e.g., steroids,&#xD;
             hormone replacement therapy.&#xD;
&#xD;
          -  Subjects who are taking amiodarone, long acting anticholinergics, e.g., atropine,&#xD;
             scopolamine, or medications or agents that can cause dry eye.&#xD;
&#xD;
          -  Subjects who have participated in a clinical trial within the 30 days prior to the&#xD;
             date on which PRK is scheduled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Ormonde, MD, FRC Ophth, FRANZCO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland Eye</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Eye Limited</name>
      <address>
        <city>Auckland</city>
        <zip>1001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2008</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Scott Bannan</name_title>
    <organization>CoDaTherapeutics</organization>
  </responsible_party>
  <keyword>Photorefractive keratectomy</keyword>
  <keyword>Re-epithelialization</keyword>
  <keyword>Nexagon</keyword>
  <keyword>PRK</keyword>
  <keyword>Coda</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

